Bio-View Ltd (TLV:BIOV)
Israel · Delayed Price · Currency is ILS · Price in ILA 16.10
0.00 (0.00%)
Apr 24, 2026, 1:44 PM IDT
Bio-View Revenue
In the year 2025, Bio-View had annual revenue of 19.93M ILS, down -22.32%. Bio-View had revenue of 10.66M in the half year ending December 31, 2025, a decrease of -38.37%.
Revenue
19.93M
Revenue Growth
-22.32%
P/S Ratio
1.08
Revenue / Employee
664.33K
Employees
31
Market Cap
21.58M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 19.93M | -5.73M | -22.32% |
| Dec 31, 2024 | 25.66M | -9.11M | -26.21% |
| Dec 31, 2023 | 34.77M | 5.62M | 19.29% |
| Dec 31, 2022 | 29.15M | -1.37M | -4.48% |
| Dec 31, 2021 | 30.51M | 4.55M | 17.54% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Teva Pharmaceutical Industries | 55.02B |
| Danel (Adir Yeoshua) | 2.90B |
| Amal Holdings A.D. | 2.18B |
| BrainsWay | 166.49M |
| Erika Carmel-Tech | 37.34M |
| Evogene | 12.28M |
| Tikun Olam-Cannbit Pharmaceuticals | 9.10M |
| XTL Biopharmaceuticals | 3.26M |